Bet on 4 Top-Ranked Stocks With Rising P/E

Zacks screened more than 7,700 stocks to identify 20 names with rising P/E ratios, accelerating earnings expectations and sustained price momentum, highlighting HTHT, INO, NMG and CCOI. The four companies carry Zacks Rank #1 or #2 ratings and reported average four-quarter earnings surprises of 14.52% for HTHT, 69.05% for INO, 106.17% for NMG and 28.41% for CCOI. The article presents the names as potential outperformers but provides no new company-specific financial results, forecasts or price targets.

Analysis

This is a weak standalone signal: the screen mechanically selects accelerating relative strength and estimate revisions, so publication can add marginal retail flow but does not establish incremental earnings durability. The key distinction is that HTHT and CCOI can be underwritten against operating KPIs, while INO and Nouveau Monde Graphite (NMG/NOU) are development-stage names where reported "earnings surprises" are often driven by expense timing, grants, or non-cash items rather than recurring cash generation. Rising multiples in the latter group increase financing and dilution sensitivity rather than signaling fundamental de-risking.

CCOI is the most actionable fundamental expression, but only if fiber/enterprise revenue growth and network utilization support leverage servicing after its prior asset-expansion cycle. Its low-cost backbone can gain share when competitors rationalize pricing, yet a higher multiple will be vulnerable to any evidence that revenue growth is purchased through price concessions or elevated capex. HTHT offers a cleaner 6-18 month operating-leverage setup if China domestic RevPAR and franchising/net unit growth sustain, but ADR valuation remains exposed to China risk-premium changes that can overwhelm hotel-level execution.

Contrarianly, a momentum screen near a breakout is more useful as a crowdedness alert than a catalyst. INO and NOU should not receive the same multiple-expansion interpretation as profitable operators: their relevant milestones are cash runway, clinical/regulatory outcomes, project financing, customer offtakes, and construction execution. QBTS appears in the supplied ticker set but has no article-specific linkage; there is no basis for a decision from this item.

Key Decisions for Investors

• Watch, do not chase, CCOI into the next earnings print; initiate a 1-3 month long only if revenue growth and EBITDA/FCF guidance are reaffirmed and net-leverage trajectory improves. Use a guidance cut or renewed capex escalation as thesis failure; target risk/reward should be at least 2:1 because momentum-only inflows are unlikely to offset a leverage repricing.
• Prefer HTHT over a China consumer/travel proxy such as FXI for a 6-12 month relative-value long, conditional on sequential RevPAR recovery and continued asset-light unit expansion. Exit on two consecutive periods of negative RevPAR versus the domestic market or material China policy/risk-premium widening.
• Avoid initiating INO or NOU/NMG purely on the screen. Establish event-driven watch alerts: INO only after independently validated clinical/regulatory progress with at least 12 months of cash runway; NOU/NMG only after binding financing/offtake terms and a credible project-cost update. Until then, downside is dominated by dilution and execution risk.
• No action in QBTS: require a separate quantum-computing catalyst, bookings/backlog data, and liquidity review before treating it as related momentum exposure.